

Universitatea de Medicină și Farmacie "Carol Davilla"

București

TEZĂ DE DOCTORAT

**CONTRIBUȚII LA DIAGNOSTICUL ȘI
TRATAMENTUL NEUROBLASTOMULUI
LA COPIL**

Coordonator Științific

Acad. Prof. Dr. Alexandru Pesamosca

Doctorand

Ninel Radu Bălănescu

2003

BIBLIOGRAFIE

1. Ambros IM, Zellner A, Roald B et al – Role of ploidy , chromosome 1p and Schwann cells in the maturation of neuroblastoma. N Engl J Med, 1996 334(23),1505-1511;
2. Arndt C, Morgenstern B, Hawkins D , Wilson D, Liedtke R, Miser J. renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol 1999; 32 : 93-96.
3. Barret A: Germ cells tumors. In Voute PA, Barret A, Bloom HJG, et al (eds): Cancer in Children, pp 185-196 , Berlin , Springer-Verlag, 1986;
4. Bell S, Parker L, Craft AW et al -False positive results in neuroblastoma screeningprogramme. Med Pediatr Oncol, 1994, 22 (3), 181-186;
5. Berthold F, Kasserbohmer R, Zieschang J – Multivariate evolution of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol, 1994, 16 (2), 107-115;
6. Bigner SH, Mark J: Chromosome and chromosomal progression of human gliomas in vivo , in vitro and athymic nude mice. Prog Exp Tumors Res 27:67-82, 1984;
7. Bigner SH, Mark J, Friedman HS, et al : Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 30:91-101, 1988;

8. Bithell JF, Steward AM: Prenatal irradiation and childhood malignancy: A review of British data form of Oxford survey, Br J Cancer 31: 271-287, 1975;
9. Bolande RP – The neurocristopathies. A unifying concept of diseases. Hum Pathol, 1974, 5(4), 409-429.
10. Bonilla MA, Cheung NK – Clinal progress in neuroblastoma. cancer Invest, 1994, 12(6) , 644-653;
11. Bower RJ, Kiesewetter WB: Mediastinal masses in infants and children. Arck Surg 112:1003-1009, 1977;
12. Bramswig JH , Heimes U, Heiermann, E, Schlegel, W, Nieschlag, E, Schellong G. The effects of different cumulative does of chemotherapy on testicular function. Cancer 1990; 65:1298-1302.
13. Brodeur GM, Pritchard J, Berthold F et al – Revisions of the international criteria for neuroblastoma diagnosis, staging and reponse to treatment. J Clin Oncol, 1993, 11(8), 1466-1477;
14. Byne J, Feras TR, Gail MH, Pee D, Connelly RR, Austin DF , et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992; 166: 788-793;
15. Caron H, van Sluis P, Beks L et al – Chromosome 1p alleic loss in neuroblastoma. J Clin Oncol, 1999, 17(2) , 345-357;

16. Caron H, van Sluis P, de Kraker J et al – Alelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. *N Engl J Med*, 1996, 334(4), 225-230;
17. Castleberry RP, Shuster JJ , Alshuler G et al – Infants with neuroblastoma have a favorable outlook after limited postoperative chemotherapy a Pediatric Oncology Group study. *J Clin Oncol*, 1998, 10(8) 1299-1304;
18. Chauvin F, Mathieu P, Frappaz D et al- Screening for neuroblastoma in France. *Med Pediatr Oncol*, 1997, 28, 81-91;
19. Combaret V, Gross N. Lasset C et al- Clinical relevance of CD44 cell surface expression and N myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. *J Clin Oncol* , 1996, 14 (1), 25-34;
20. De Bernardi B, Conte M, Mancini A et al – Localized resectable neuroblastoma , results of the second study of the italian Cooperative Group for Neuroblastoma. *J Clin Oncol*, 1995,13 (4), 884-893.
21. De Cou JM, Bowman LC, Rao BN et al – Infants with metastatic neuroblastoma have improved survival with resection of the primary tumour. *J Pediatr Surg*, 1995, 30(7), 937-940;
22. De Kraker J, Hoefnagel CA, Caron H et al – First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. *Eur J Cancer* , 1998, 51 A (8), 800-802;

23. de Vathaire F, Hawkins M, Campbell S, Oberlin O, Raquin M-A, Schlienger J-Y et al. Br J Cancer 1999; 79:1884-1892.
24. Dominici C, Nicotra MR, Digiesi G et al – Immunohistochemical detection of high – affinity nerve growth factor receptor in neuroblastoma. Eur J Cancer 1995, 31 A(4), 444-446;
25. Evans AE, D’Angio GJ, Randolph J – A proposed staging for children with neuroblastoma. Children’s cancer study group A. Cancer , 1971, 27 (2) , 374-378;
26. Evans AE, Silber JH , D’Angio GJ – Successful management of low stage neuroblastoma without adjuvant therapies. J Clin Oncol, 1996, 14, 2504-2510;
27. Favrot MC, Ambros P, Schilling F et al – Comparison of the diagnostic and prognostic value of biological markers in neuroblastoma. Am Oncol, 1996, 7, 607 – 611;
28. Fraumeni JF Jr: Clinical patterns of familial cancer. In Mulvihill JJ. Miller RW, Fraumeni JF Jr (eds): Genetics of Human Cancer, pp 223-231, New York, Raven Press, 1977;
29. Garaventa A, de Bernardi B, Pianca C et al – Localised but unresectable neuroblastoma, treatment and outcome of 154 cases Italian Cooperative Group for Neuroblastoma J. Clin Oncol, 1993, 11(9), 1770-1779;

30. Gehring M, Berthold F, Elder L et al – The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. *Cancer Res*, 1995, 55(22), 5366-5369;
31. Gerres L, Bramswig JH, Schlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin's disease. *Cancer* 1998;83: 2217-2222.
32. Greenberg RS, Shuster JL Jr: Epidemiology of cancer in children *Epidemiol Rev* 7:22-48 , 1985;
33. Greffe J, Lemoine P, Lacroix C et al – Increased serum levels of neuron specific enolase in epileptic patients and after electroconvulsive therapy. *Clin Chim Acta*, 1998, 344(2), 199-208;
34. Griffin CA, Hawkins AL, Packer RJ, et al : Chromosome abnormalities in pediatric brain tumors. *Cancer Res* 48:175-180, 1988;
35. Guglielmi M, de Bernardi B, Rizzo A et al – Resection of primary tumour at diagnosis in stage IV S neuroblastoma, does it affect the clinical course? *J Clin Oncol*, 1996, 14(5), 1537-1544;
36. Haase GM Atkinson JB, Sttam DO et al – Surgical management and outcome of locoregional neuroblastoma, comparison of the Childrens cancer Group and the international staging systems. *J Pediatr Surg*, 1995, 30(2), 289 – 294;
37. Hartmann O, Favrot MC – Neuroblastomes Aspects cliniques et therapeutiques actuels Apports de la biologie moderne. *Rev Prat*, 1993, 43(17), 2182-2186;

38. Hicks MJ, Mackey B – Comparison of ultrastructural features among neuroblastic tumors, maturation from neuroblastoma to ganglioneuroma. *Ultrascurt Pathol*, 1998, 22(4), 311-322;
39. Honig PJ, Charney EB: Children with brain tumor headaches. *Am J Dis Child* 136:121 –124, 1982;
40. Ikeda H, Suzuki N, Takahashi A et al – Dopa metabolism in screening detected and non-screening detected neuroblastoma. *Pediatr Hematol Oncol*, 1996, 13(1), 21-32.
41. International Agency for Research on Cancer. parkin DM, Stiller CA, Draper GJ, et al (eds): *International Incidence of Childhood Cancer* , IARC Scientific Publication No,87, Lyon, IARC Scientific Publications ,1988
42. Ion Dorin Bleahu – Progrese clinice in neuroblastoame, *Rev Română de pediatrie*, Vol L, Nr 4, 2001;
43. Jennings RW, La Quaglia MP, Leong K et al – Fetal neuroblastoma prenatal diagnosis, *J Pediatr Surg*, 1993, 28(9), 1168-1174;
44. Joshi VV, Rao PV, Cantor AB et al – Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. A clinicopathologic study o 223 cases from the Pediatric Oncology Group. *Cancer* , 1996,77(8), 1582-1588
45. Kist-van Holthe JE, van Zwet JML, Rand R, van Weel MH, Vossen JMJJ. Bone marrow transplantation in children : consequences for renal

- function shortly after and 1 year post-BMT. Bone Marrow Transplant 1998; 22: 559-564.
46. Knudson AG: Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 45:1437, 1985;
47. Kondo M, Kojima J, Horibe K, Kato K, Matsuyama T. Hemolytic uremic syndrome after allogeneic or autologous hematopoietic stem cell transplantation for childhood malignancies. Bone Marrow Transplant 1998; 21:281-286.
48. Kremens B, Klingebiel T, Herrmann F et al – High dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. Med Pediatr Oncol, 1994, 23(6), 470-475.
49. Kushner BH, Cheung KV, La Quaglia MP et al – International Neuroblastoma Staging System stage 1 neuroblastoma, A prospective study and literature review. J Clin Oncol, 1996, 14(7) , 2174-2180;
50. Kushner BH, Cheung N-KV, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment – related myelodysplasia/leukemia : the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998, 16:3880-3889.
51. Larsen RL, Barber G, Heise CT, August CS. Excercise assessment of cardiac function in children and young adults before anf after bone marrow transplantation. Pediatrics 1992; 89: 722- 729.
52. Lascari AD: Hematological Manifestations of Childhood Diseases. New York, Thieme- Stratton, 1984;

53. Leiper AD, Stanhope R, Lau T, Grant DB, Blacklock H, Chessells JM et al. The effect of total body irradiation and bone marrow transplantation during childhood and adolescence on growth and endocrine function. *Br J Haematol* 1987; 67:419-426
54. Li FP, Gimbriere K, Gelber RD, Sallan SE, Flamant F, Green DM et al. Outcome of pregnancy in survivors of Wilms' tumor. *J AM Med Assoc* 1987; 257:216-219.
55. Li FP, Jamison DS, Meadows AT : Questionnaire study of cancer etiology in 503 children. *J Natl Cancer Inst* 76:31,1986;
56. Li FP : Cancer families : Human models of susceptibility to neoplasias, *Cancer Res* 48:5381, 1988;
57. Li FP : Cancers in children. In Schottenfeld D, Fraumeni JF Jr (eds): *Cancer Epidemiology and Preventio*, pp 1012 – 1024, Philadelphia WB Saunders, 1982;
58. Lipshultz SE, Sallan SE. Cardiac abnormalities in long-term survivors of childhood malignancy. *J Clin Oncol* 1993; 11:1199-1203.
59. Maris JM, Chatter J, Meadows AT et al – Familial neuroblastoma a three generation pedigree and a association with Hirschsprung disease. *Med Pediatr Oncol*, 1997 , 28, 1-5
60. Mathieu P, Frappaz D, Chauvin F et al – A 9 years (1990-1998) neuroblastoma screening feasibility study in France. *Eraly Hum Dev*. 1999, 49, 189-199;

61. Matthay K, Lukens J, Haase G et al – Outcome and prognostic factors for 1008 children with neuroblastoma treated from 1989-1995 on Children Cancer Group (CCG) protocols. *Advances in Neuroblastoma Research* , Abstract B9, 1996;
62. Mayfield JK, Riseborough EJ, Jaffe N, Nehme AM. Spinal deformity in children treated for neuroblastoma. *J Bone Surg* 1981; 63:183-193.
63. McKenna BJ, Schwinn CD, Soong KY, et al : Sarcoma of the osteogenic series : analyses of 552 cases. *J Bone Joint Surg* 48A:1-26, 1966;
64. Meister LA, Meadows AT. Late Effects of Childhood Cancer Therapy. *Curr Probl* 1993; March: 102-131.
65. Merteno A, Neglia J, Yasui Y, Potter J, Nesbit Jr M, Ruccione R et al. Mortality rates in causes of death in 5-years survivors of childhood and adolescent cancer. *Proc Am Soc Clin Oncol* 1999; 18:569a.
66. Miller RW: Boice JD Jr: Radiogenic cancer after prenatal exposure. In Upton AC, Albert RE, Burns FJ, Shore RE (eds): *Radiation Carcinogenesis* , pp 379 – 386, New York, Elsevier, 1986;
67. Miller RW: Relation Between cancer and congenital malformations: The value of small series, with a note on pineal tumors in native and migrant Japanese, *Isr J Med Sci* 7:1461-1464, 1971;
68. Mulvihile Y.: Childhood cancer, the Environment and Heredity, in Pizzo A.P., Poplack D. (red). *Principles and Practice of Pediatric Oncology* , JB., Lippincott Company, Philadelphia, 1996

69. Mulvihill JJ, Camenni-Otero D, Schechter AN: Medical Genetics: 1990, Bethesda, Foundation for Advanced Education in the Sciences, 1990;
70. Mulvihill JJ, Clinical observations of ecogenetics in human cancer. Ann Intern Med 92:809 – 813, 1980;
71. Mulvihill JJ: ecogenetic origins of cancer in the young: Environmental and genetic determinants. In Levine AS (ed) : cancer in the Young, pp 13-27, New York, Masson, 1982;
72. Murphree A, benedict W: Retinoblastoma : Clues to human oncogenesis Sciences 223:1028-1033, 1984;
73. Nakagawara A, Arima M, Scvarda NJ et al- Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med, 1993, 328(12), 847-854;
74. National Cancer Institute. Ries LA, Hankey BF , Miller BA, et al (eds): Cancer Statistic Review 1973-88. NH Publication No. 91-2789, Bethesda, 1991;
75. Neel JV: Update of the genetic effects of ionizing radiatio. JAMA 266; 698 – 701, 1991;
76. Neglia J, Mertens A, Yasui, Hammond S, Friedman D, Donaldson S et al. Risk of secondary primary neoplasms (SPNs) in survivors of childhood cancer – initial analysis of the Childhood Cancer Survivor Study (CCSS). Proc Am Soc Clin Oncol 1999; 18:557a.
77. Nellhaus G: Brain tumors in childhood. Pediatr Ann 2:18-38, 1974;

78. Nesbot M.E. Yo – Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer, in Pizzo A. P., Poplack D. (red) Principles and Practice of Pediatric Oncology , JB, Lippincott Company , Philadelphia, 1996;
79. Neve F, Foot ABM, Michon J, Fourquet A, Zucker JM, Boule M. Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation, and autologous bone marrow transplantation for metastatic neuroblastoma. *Med Pediatr Oncol* 1999; 32:170 – 176.
80. Nishi M, Miyake H, Takeda T at al – Mass screening of neuroblastoma in Japan. *Am J Pediatr. Hematol Oncol*, 1992, 14(4), 327-331;
81. Parker B.R., Sheila G., Moore: Imaging Studies in the Diagnosis of Pediatric Malignancies, in Pizzo A. P., Poplack D. (red) Principles and Practice of Pediatric Oncology, JB, Lippincott Company , Philadelphia, 1996;
82. Parsons SK, Neault MW, Lehman LE, Brennan LL, Eickhoff CE, Kretschmar CS, Diller LR. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. *Bone Marrow Transplant* 1998; 22:669-674.
83. Plantaz D, Rubie H, Michon J et al – The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease, a prospective study. *cancer*, 1996, 78(2), 311-319;

84. Pritchard DJ, Dahlin DC, Dauphine RT, et al : Ewing's sarcoma J. Bone Joint Surg 57A:10-16 , 1975;
85. Reaman G.H. – Special Consideration for the Infant with Cancer, in in Pizzo A. P., Poplack D. (red) Principales and Practice of Pediatric Oncology, JB, Lippincott Company , Philadephia, 1996;
86. Rubie H, Hartmann O, Michon J et al – N myc gene amplification is a major prognostic factor in neuroblastoma, a raport from POG. Med Pediatr Oncol, 1998,30, 284-288;
87. Schwarz KB, Driver J, Lewis IJ et al – Positive m IBG scanning at the time of relapse in neuroblastoma. Br J Radiol, 1997, 70, 90-92;
88. Shankar SM, Bunin NJ, Moshang T. Growth in children undergoing bonemarrow transplantation after busulfan and cyclophosphamide conditioning. J Pediatr Hematol Oncol 1996; 18:362-366.
89. Sharom SH, Donaldson MH, Duckett JW, Wein AJ. Formalin treatment for intractable hemorrhagic cystitis. Cancer 1976; 38:1785-1789.
90. Siimes MA, Rautonen J, Makiperna A, Sipila I. Testicular function in adult males surviving childhood malignancy. Pediatr Hematol Oncol 1995; 12:231-241.
91. Silber JH, Littman Ps, meadows AT. Stature loss following skeletal irradiation for childhood cancer. J Clin Oncol 1990; 8: 304-312.
92. Sklar, CA, Kim TH, Ramsay NKC. Thyroid dysfunction among long-term survivors of bone marroe transplantation. Am J Med 1982; 73:688-694.

93. Sklar CA, Robinson LL, Nesbit ME et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia : a raport from the Children's cancer Study Group, J Clin Oncol 1990; 8:1981-1987.
94. Smith S, Reeves BR, Wong L, Fisher C: A consistent chromosome translocation in synovial sarcoma. cancer genet Cytogenet 26:179-180, 1987;
95. Stram DO, Matthay KK , Oleary M et al – Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma, a raport of CCG, J Clin Oncol 1996, 14, 2417-2426;
96. Strother D, Shauster JJ, Mc Williams N et al – Results of pediatric oncology protocol 8104 for infants with stage D and Ds neuroblastoma. J Pediatr. Oncol, 1995, 17(3), 254-259;
97. Suita S, Zaizen Y, Sera Y et al – neuroblastoma in infants aged less than 6 months. A report from the POG. J Pediatr Surg, 1995, 30(5), 715-721;
98. Tanaka T , Tanabe M, Sugimoto T at al – Age related profile of neuroblastoma. Acta Pediatr japan, 1995, 37(2), 154-159;
99. Testa JR: Chromosome translocation in human cancer. Cell Growth Differentiation 1:97-101,1990
100. Tsunematusu Y. Personal communication.

101. Tucker MA, Meadows AT, Boice JD, et al: Cancer risk following treatment of childhood cancer. In Boice JD, Fraumeni JF (eds): Radiation Carcinogenesis: Epidemiology and Biological Significance , New York, Raven Press, 1984;
102. Tucker MA, Meadows AT, Bioce JD, Hoover RN, Fraumeni JF. Cancer risk following treatment of childhood cancer . In: Boice JD and Fraumeni JF, editors Radiation Carcinogenesis Epidemiology and Biological Significance. New York: Raven Press; 1980; 211-225.
103. Tucker MA, Morris Jones PH, Boice JD Jr, Robinson LL, Stone BJ, Stovall M et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991; 51: 2885-2888.
104. Turc – Carel C, Lizard-Nacol S, Justrabo E, et al : Consistent chromosomal translocation in alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 19:361-362,1986;
105. Turc – Carel C, Philip I, Berger MP, et al : Chromosome study og Ewing’s saracoma (ES) cell lines : Consistency of a reciprocal translocation t (11,22) (q 24;q12). Cancer Genet Cytogenet 12:1-19, 1984;
106. Upton AC, Albert RE, Bums FJ, Shore RE (eds): Radiation Carcinogenesis, New York , Elsevier 1986;
107. Voute PA, van der Kleij AJ, de Kraker J et al – Clinical experience with radiation enhancement by hyperbaric oxygenin children with recurrent neuroblastoma stage IV. Eur J Cancer, 1995, 31A(4), 596-600;

108. Walterhouse DO, Meadows AT: Late effects of childhood cancer therapy. In Plowman PN, McElwain TJ, Meadows AT (eds) : Complications of Cancer Management , pp 95-113, Oxford Butterworth/Heinemann, 1991;
109. White P, Maris J, Sulman E et al – Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma. Advances in Neuroblastoma research , Abstract 12, 1996;
110. Willi SM, Cooke K, Goldwein J, August CS, Olshan JS, Moshang T. Growth in children after bone marrow transplantation for advanced neuroblastoma compared with growth transplantation for leukemia or aplastic anemia. J Pediatr 1992; 120:726-732.
111. Woods WG, Tuchman M, Robinson LL et al – A population based study of usefulness of screening for neuroblastoma. Lancet, 1996, 348, 1682-1687.
112. Ylan R.K. – Genetics of pediatric Tumors: The Causes and Consequences of Chromosomal Aberration , in Pizzo A.P., Poplack D. (red) Principles and Practice of Pediatric Oncology, J.B., Lippincott Company, Philadelphia , 1996.
113. Prof. Dr. L. M. Popescu, Dr. M. E. Hinescu – Elemente de biologie celulară și moleculară, Tratat de patologie chirurgicală (sub redacția Prof. Dr. N. Angelescu), pag. 55-56 , Editura Medicală , București, 2001.
114. Journal of the National Cancer Institute , March 1, 2000, vol. 92, no. 5, p. 366-368, Can HER-2 status predict response to cancer therapy N.J. Nelson.

115. G. M. Brodeur , T. Sawada, Y Tsuchida, P.A. Voute – Neuroblastoma, Elsevier, 2000, p.31 -32; 85-95.
116. A. Pesamosca, N. Bratu et al – Noutăți în diagnosticul și tratamentul neuroblastomului, Sesiunea de Comunicări Științifice, Călărași , 1986.
117. Whitley R.J., Kimberlin D.W.- Viral encephalitis, *Pediatric Rev.* 20, pp. 192-198, 1999.
118. Roizman B., Sears A. E., Herpes simplex viruses and their replication. In Fields B. N., Knipe D. M., Howley P. M. eds., *Fields' Virology*, 3-rd ed, Lippincott-Raven Publishers, PA, 1996, pp. 2231-2295.
119. Freeman S.M., Whartenby K. A., Freeman J.L., Abboud C. N., Maroggi A. J. – In situ use of suicide genes for cancer therapy , *Seminars Oncol.*, pp. 23, 31-45, 1996.
120. McLaughlin J., Roozendal B., Dumas T., Gupta A., Ajilore O. Hsieh J., Ho D., Lawrence M., McGaugh J. L., Sapolsky R. – Sparing of neuronal function post-reisure with gene therapy , *Proc. Natl. Acad. Sci USA*, 97: 12804 – 12809, 2000.
121. Kim T. W., Tanzi R. E. – Presenilins and Alzheimer's disease, *Curr. Opin. Neurobiol.* 7:638 – 688, 1997.
122. Sawa A. – Neuronal cell death in Down's Syndrome. *J. Neural Transm.*, suppl. 57:87 – 97, 1999.

123. Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma
124. Jaume Mora, M. D.1 , William L. Gerald , M. D. PH. D1 , Jing Qin, PH. D2 , Nai- Kong V. Cheung , M.D., PH. D.3
125. Brodeur GM., Castelberry RP. – Neuroblastoma in Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology , 3-rd edition, chapter 29, Philadelphia : Lippincott – Raven Publishers , pp. 761 – 797, 1997.
126. Hartmann O., Valteau-Couanet D., Vassal G. et al – Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantations : a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant, 23: 789-795, 1999.
127. Matthay K. K., Villablanca J. G., Seeger R. C. et al – Treatment of high-risk neuroblastoma with intensive chemotherapy , radiotherapy , autologous bone marrow transplantation and 13-cis retinoic acid; N. Engl. J. Med. ; 341: 1165-1173, 1999.
128. Frappaz D., Michon J., Coze et al – LMCE, treatment strategy : results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis J. Clin. Oncol.; 18: 468 – 476, 1999.
129. Stram D. O., Matthay K. K., O’leary M. et al – Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastomas: A report of two

- concurrent children's Cancer Group Studies J. Clin. Oncol.; 4: 2417-2426, 1996.
130. Minard V., Hartmann O. Peyroulet M.V. et al – Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of Pediatric Oncology, Br. J. Cancer; 83: 973-979, 2000.
131. Moss J., Reynolds C. P., Sather H. N. et al – Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N. Engl. J. Med.; 324:219 – 226, 1991.
132. Seeger R.C., Reynolds C.P. Gallego R. et al – Quantitative tumor cell content of bone marrow and blood as a predictor of outcome stage IV neuroblastoma: a children's Cancer Group Study. J. Clin. Oncol.; 18: 4067 – 4076, 2000.
133. Seeger R. C., Brodeur G. M., Sather H. et al – Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313:1111 – 1116, 1985
134. Brodeur G.M. Seeger R. C., Schwab M. et al – Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage science; 224: 1121 – 1124, 1984
135. Maris J. M., Matthay K. K. – Molecular biology of neuroblastoma J. Clin. Oncol.; 17:2264 – 2279, 1999.

136. Fong C. T., White P. S., Peterson K. et al – Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. *Cancer res.*; 52: 1780- 1785, 1992.
137. Weiss M. Y., Guo C., Shusterman S. et al – Localization of a hereditary neuroblastoma predisposition gene to 16 p 12 – p 13. *Med. Pediatr. Oncol.*; 35: 526 -530, 2000.
138. Mora J., Cheung N. K. V., Chen L. et al- Loss of heterozygosity at 19q13,3 is associated with locally aggressive neuroblastoma. *Clin. Cancer Res.*; 7: 1358 – 1361, 2001.
139. Takita J., Hayashi J., Takey K. et al – Allelic imbalance of chromosome 18 in neuroblastoma. *Eur. J. Cancer*; 36: 508 – 513, 2000.
140. Hirai M., Yoshida S., Kashiwagi H. et al – 1q23 gain associated with progressive neuroblastoma resistant to aggressive treatment. *Genes Chromosomes Cancer*; 25:261 – 269, 1999.
141. Cheung N. V., Heller G. – Chemotherapy dose intensity correlates strongly with response , median survival and median progression – free survival in metastatic neuroblastoma. *J. Clin. Oncol.*; 9: 1050 -1058, 1991.
142. Mora J., Gerald W., Chen L. et al – Survival analysis of clinical, pathologic and genetic features in neuroblastoma presenting as local – regional disease cancer ; 91: 435 – 442, 2001.

143. Cohn S. L., Look A. T., Joshi V. V. et al – Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. *Cancer Res.*; 55: 721 – 726, 1995.
144. Bowman L. C., Castleberry R. P., Cantor A. et al – Genetic staging of unresectable or metastatic neuroblastoma in infants : a Pediatric Oncology Group study. *J. Natl. Cancer Inst.*; 89:373 – 380, 1997.
145. Nickerson H. J., Matthay K. K., Seeger R. C. et al- Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's cancer Group study. *J. Clin. Oncol.*; 18 :477 – 486, 2000.
146. Kushner B. H., La Quaglia M. P., Bonilla M. A. et al – Highly effective therapy for stage 4 neuroblastoma in children over 1 year of age. *J. Clin. Oncol.*; 12 : 2607 – 2613, 1994.
147. Kushner B. H., O'Reilley R. J. La Quaglia M. P., Cheung N. K. – High dosing and dose – rate using cyclophosphamide in ablation of neuroblastoma cancer; 66: 1095 – 1100, 1996.
148. Shimada H., Ambros I. M., dehner L. P. et al – The International Neuroblastoma Pathology Classification (the Shimada system). *Cancer.*, 86: 364 – 372, 1999.
149. Kretschmar C. S., Franz C. N., Rosen E. M. et al- Improved prognosis for infants with stage IV neuroblastoma. *J. Clin. Oncol.*; 2: 799 -803 , 1984.

150. Paul S. R., Tarbell N. J., Korf B. et al – Stage IV neuroblastoma in infants. Long – term survival. *Cancer.*; 67: 1493 – 1497, 1991.
151. De Bernardi B., Pianca C., Boni L. et al – Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma *Cancer*; 70: 1625 – 1633, 1992.
152. Thompson P. M., Marib J. M., Hogarty M. D. et al – Homozygous deletion of CDRN2A (p16INKA 4a - / p14 ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. *Cancer Res.*; 61: 679 – 686, 2001.
153. Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo – B. O. Popescu, M. Oprica, Maria Sajin, Cristina L. Stanciu, O. Bajenaru, Andreea Predescu, Cristina Vidulescu, L. M. Popescu, *J. Cell. Mol. Med.* Vol. 6, No.4, 2002, pag. 555 – 569.
154. Nat R., Cretoiu D., Popescu L. M., In vitro differentiation of human embryonic neural stem cells, *J. Cell. Mol. Med.* Vol. 5, 325 – 325, 2001.
155. Prof. Dr. A. Pesamosca, Dr. Nina Bratu, Dr. G. Topor, Dr. D. Motoi – Considerații asupra diagnosticului și tratamentului neuroblastoamelor toracice și abdominale la copil, *Congresul Național de Chirurgie Pediatrică*, Craiova, 1992.
156. Jose Luis Perez Garcia, Maria Gloria Ruiz – Ilundain , et al – The role of extreme phenotype selection studies in the identification of clinically relevant genotypes in cancer research, *Cancer* 95/7, Oct. 1,

2002, Clinical Research Department, Eli Lilly and Company, Madrid, Spain.

157. Todd J. A. – Interpretation of results from genetic studies of multifactorial diseases, *Lancet*, 1999; 354.
158. Miller R. W. – Death from childhood cancer in sibs, *N. Engl. J. Med.* 1968, 279; 122-126
159. Frederique Sauvat, Sabine Sarnacki, Herve Brisse et al – Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicentenary study, *Cancer*, 94/9, May 1-st, 2002.
160. Acharya S., Jayabose S., Kogan S. J. Et al – Prenatally diagnosed neuroblastoma, *Cancer*, 1997; 80: 304 – 310.
161. Yamamoto K., Hanada R, Kikuchi A. – Spontaneous regression of localized neuroblastoma detected by mass screening, *J. Clin. Oncol.*, 1998; 16; 1265 – 1269.
162. Yamagiwa I, Obata K., Saito H. – Prenatally detected cystic neuroblastoma, *Pediatr. Surg. Int.*, 1998; 13: 215 – 217.
163. Granata C., Fagnani A. M., Gambini C. et al – Features and outcome of neuroblastoma detected before birth, *J. Pediatr. Surg.*, 2000; 35: 88 – 89.
164. Woods W. G., Tuchman M., Robinson L. L. et al – A population based study of the usefulness of screening for neuroblastoma, *Lancet*, 1996; 348: 1682- 1687.

165. T. Zamfir, O. C. Iacob, Gh. Răducanu – Neuroblastomul la copil, Consfătuirea Centrală de Oncologie Pediatrică, Iași, 1988.
166. Kaneko M., Iwakawa M., Ibebukuro K., Ohkawa H. – Complete resection is not required in patients with neuroblastoma under 1 year of age, *J. Pediatr. Surg.*, 1998; 33: 1690 – 1694.
167. Yamamoto H., Yoshida M., Sera Y. – Laparoscopic surgery for neuroblastoma identified by mass screening, *J. Pediatr. Surg.*, 1996; 31: 385 – 388.
168. J. Zhu, W. Song, H-Lin, D. C. Young, S. Jan, C. S. Chen – Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis inducing agents, *Journal of the National Cancer Institute*, Dec. 4, 2002, vol. 94, no. 23, p. 1745 – 1757.
169. Garrett M., Brodeur L. M. And Akira Nakagawa – Bazele moleculare ale heterogenității in neuroblastom , *The American Journal of Pediatric Hematology / Oncology*, L4, 1992, pag. 116 – 119.
170. Matthay K. K., Villablanca J. G., Stram D. O., Harris R. E., Shimada H., Brodeur G. M. – Tratatamentul neuroblastomului cu risc crescut cu chimioterapie intensivă, radioterapie și transplant de măduvă autolog și acid 13-cis retinoic, *New England Journal of Medicine*, 341 (16) : 1165 – 73, 1999, Oct. 14.
171. Pittenger G. L., Malik R. A., Barends N., Boulton A. J., Vink A. I. – Deficitul de fibre specifice în polineuropatia sensorimotorie diabetică corespunzând citotoxicității din celulele neuroblastomului, la pacienții cu diabet, *Diabetes Care*, 22 (11) : 1839 – 1844, 1999, Nov.

172. Seger R. C., Reynolds C. P., Gallego R., Stram D. O., - Conținutul cantitativ de celule tumorale din măduva osoasă și sânge ca indicator de gravitate în stadiul IV al neuroblastomului, *Journal of Clinical Oncology*, 18 (24) : 4067 – 4076, 2000, Dec. 19.
173. Thomas H., Boddy A. V., English M. W., Hobson R. – Validare prospectivă a funcției renale de bază prin dozarea carboplatinei la copiii cu cancer, *Journal of Clinical Oncology*, 18(21): 3614 – 3621 , 2000, Nov. 1.
174. Minard V., Hartman O., Peyroulet M. C., Michon J., Coze C. – Reacție adversă la copiii cu neuroblastom metastatic, amplificare N-myc și/sau leziuni osoase, *British Journal of Cancer* , 83 (8) : 973 – 9 , 2000, Oct.
175. Kohler J. A., Imeson J., Lie So – Un studiu randomizat al acidului 13-cis retinoic la copiii cu neuroblastom avansat după terapie „high doses” , *British Journal of Cancer* , 83 (9) : 1124 – 1127 , 2000, Nov.
176. Moss T. J. – Date clinice despre cancerul minim rezidual la pacienții cu tumori solide, *Cancer & Metastases Reviews*, 18 (1): 91 – 100, 1999.
177. Carmella A., Ruth C. – Studiu de caz : posibil stres posttraumatic la copil cu cancer, *Cancer*, vol. 39 (2), feb., 2000, pag. 257 – 260. American Academy of Child and Adolescent Psychiatry.
178. Berrak S. G., Canpolat C., Berik P. – Cefepim and ceftazidime in combination with amikacin in febrile neutropenia of childhood: Which

regimen is more effective? *European Journal of Cancer*, 35 (suppl. 4), p. 115, 1999.

179. Kerbel R. S., Vitoria – Petit A., Klement G., Rak J. – „Accidental” angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples, *European Journal of Cancer*, 36 (10) : 1248 – 1257, 2000, June.